Whether GPR may be superior to other NITs in evaluating regression of fibrosis after long-term antiviral suppression of HBV or predicting liver-related end-points, such as hepatic decompensation or HCC deserves further investigation. This evidence concerns the gene ALDH18A1 and hepatocellular carcinoma.